Shares of Aquestive Therapeutics (NASDAQ:AQST) rose on Wednesday after the company announced that the U.S. regulators had issued two new patents covering its allergy therapy Anaphylm, which is currently under FDA review. The Warren, New Jersey-based biopharma said that the U.S. Patent ...